No.3
ボリバン幅がスクイーズ、出来高減少。上げ圧高まっている。
RBC GBT Initiating coverage with an Outperform rating and a $75 PT. Oxbryta as a first-in-class sickle hemoglobin (HbS) polymerization inhibitor with potential to become standard of care in sickle cell disease
返信
投資の参考になりましたか？
